CD160 Expression in Corneal Vessels

CHU de Reims

Status: Enrolling

Conditions: CD160; Corneal Graft Rejection; Angiogenesis; Lymphangiogenesis

Treatments: Biological: Immunohistochemistry and clinical analyses on patients and corneas

Study type: Observational

Funder types: Other

Identifiers

NCT05009407

PO21062

Details and patient eligibility

About

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Full description

After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included.

Routine general and eye examination including cornea photographs will be performed.

During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

inclusion criteria :

• 18-year-old or more patients
• enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
• considered able to give an informed written consent exclusion criteria :
• none

Trial design

20 participants in 2 patient groups

HOSTS

Description:

patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor

Treatment:

Biological: Immunohistochemistry and clinical analyses on patients and corneas

DONORS

Description:

grafts from donors that would be analyzed

Treatment:

Biological: Immunohistochemistry and clinical analyses on patients and corneas